Wan Xiao-Mei, Chu Rui-Xue, Gong Hua-Qing
College of Medicine, Qingdao University, Qingdao 266071, Shandong Province, China.
Int J Ophthalmol. 2011;4(2):179-81. doi: 10.3980/j.issn.2222-3959.2011.02.14. Epub 2011 Apr 18.
To investigate a new, safe and effective injection method for strabismus patients. Botulinum toxin type A (BTXA) was injected by pulling the extraocular muscles with a minimally-invasive technique into the ocular surface, and it was ensured that the extraocular muscles was maintained in the suspended state.
A total of 32 patients with different types of strabismus were treated at our institution from February to October 2010. A small conjunctival incision (≤2mm) was made under a microscope. The extraocular muscles were pulled out with a hook to ensure an elevated position compared with the wall of eyeball. The muscle fiber was clearly seen through the conjunctiva and BTXA was injected at a small angle under the microscope. The deviation angles before and after the injection were recorded. All patients were followed up at 5 and 30 days after the operation. Recovery was defined as abolition of diplopia in straight-ahead gaze and anteroinferior gaze and the symptoms of giddiness disappeared thoroughly. Eyeball position was essentially normal. Improvement was defined as basic disappearance of diplopia in straight-ahead gaze and anteroinferior gaze; restriction of action of paralytic muscle improved. If most of the symptoms and signs still existed and disturbed normal work and life, the treatment was determined to be invalid. The injection dose for patients of 5 to 10 prism diopter (PD), 11 to 20PD, and ≥21PD was 1u, 3u and 4u to 5u, respectively.
Of the 32 treated patients, 11(34.4%) were cured, and 18(56.3%) were improved at 5 days after the operation; 12(40%) were cured, and 15(46.9%) were improved at 30 days. Five patients (15.6%) who had unsatisfactory response after BTXA injection at 30 days received repeated injections or underwent strabismus surgery. Ptosis was present in 2.5% of the injected eyes. No retrobulbar hemorrhage or ocular perforation was found in any eye.
It is safe and efficient to inject BTXA by pulling extraocular muscles with a minimally-invasive technique under the microscope to make the muscles separated from the wall of eyeball.
探讨一种针对斜视患者的新型、安全且有效的注射方法。采用微创技术将眼外肌牵拉至眼表,注射A型肉毒杆菌毒素(BTXA),并确保眼外肌保持悬吊状态。
2010年2月至10月,我院共治疗32例不同类型斜视患者。在显微镜下做一个小的结膜切口(≤2mm)。用钩子将眼外肌拉出,确保其相对于眼球壁处于抬高位置。透过结膜可清晰看到肌纤维,在显微镜下以小角度注射BTXA。记录注射前后的斜视角度。所有患者在术后5天和30天进行随访。治愈定义为正前方注视和前下方注视时复视消失,头晕症状彻底消失,眼球位置基本正常。改善定义为正前方注视和前下方注视时复视基本消失,麻痹肌的作用受限改善。如果大部分症状和体征仍然存在并干扰正常工作和生活,则判定治疗无效。5至10棱镜度(PD)、11至20PD以及≥21PD的患者注射剂量分别为1u、3u和4u至5u。
32例接受治疗的患者中,术后5天11例(34.4%)治愈,18例(56.3%)改善;术后30天12例(40%)治愈,15例(46.9%)改善。30天BTXA注射后反应不满意的5例患者(15.6%)接受了重复注射或斜视手术。注射眼有2.5%出现上睑下垂。所有眼睛均未发现球后出血或眼球穿孔。
在显微镜下采用微创技术牵拉眼外肌注射BTXA,使肌肉与眼球壁分离,是安全有效的。